T1	Outcomes 27 35	mesylate
T2	Outcomes 97 129	gastrointestinal stromal tumors.
T3	Outcomes 276 293	imatinib mesylate
T4	Outcomes 572 580	imatinib
T5	Outcomes 845 851	Cancer
T6	Outcomes 893 901	Oncology
T7	Outcomes 956 964	imatinib
T8	Outcomes 984 993	imatinib.
T9	Outcomes 1191 1199	imatinib
T10	Outcomes 1287 1295	imatinib
T11	Outcomes 1313 1343	progression-free survival time
T12	Outcomes 1550 1559	median OS
T13	Outcomes 1614 1634	adverse events (AEs)
T14	Outcomes 1657 1726	nausea, fatigue, skin rash, gastrointestinal complaints, and myalgia.
T15	Outcomes 1754 1777	abnormality was anemia.
T16	Outcomes 1793 1796	AEs
